TransThera Sciences (Nanjing), Inc. (2617.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$8.48 (-4.34%) as of
Key statistics
- Market cap
- 3.46B
- Forward P/E
- -22.55
- EPS (TTM)
- -0.760
- Dividend yield
- 0.00%
- 52-week range
- 8.350 – 246.000
- Revenue (TTM)
- 35.45M
- Profit margin
- 0.00%
- Analyst target
- HK$19.06
- Volume
- 2.84M
About TransThera Sciences (Nanjing), Inc.
TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a multi-kinase inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors for multiple disease; and Akeso, Inc. for the treatment of hepatocellular carcinoma. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Nanjing, China
- Employees
- 132
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.